source
- FDA issues CRL for Summit Therapeutics' ivonescimab, underscoring need for overall survival dataThe FDA sent a complete response letter to Summit Therapeutics, rejecting its biologics license application for ivonescimab, a PD-1xVEGF antibody being tested in EGFR-mutated non-small cell lung ca…
- Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancersEli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…